Navigation Links
New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma
Date:8/13/2012

PRINCETON, N.J., Aug. 13, 2012 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with its client, ZZ Biotech, on process development and production of a new potential therapeutic for ischemic stroke. The drug, known as 3K3A-APC, is a form of activated human Protein C whose molecular structure has been intentionally modified to remove the undesirable side effect of bleeding. ZZ Biotech recently announced the start of Phase 1 trials with this material.

(Logo: http://photos.prnewswire.com/prnh/20120214/PH53290LOGO )

Protein C becomes an active protease upon enzymatic activation, a step that is carried out during the purification process. Once activated, this protease can degrade itself, since enzymes are also proteins. Additional complexity arises from the production of isoforms as well as modified amino-acid structures that are important to the activity of 3K3A-APC. Working together with scientists from ZZ Biotech and its collaborators, Laureate's scientists were relentless in overcoming these challenges to produce clinical-trial material.

Kent E. Pryor, Ph.D., Chief Operating Officer of ZZ Biotech said, "We are pleased to have been able to take a difficult protein out of the research lab and put it into the clinic. Our partnership with Laureate has been integral to turning an idea into a potential new human therapeutic."

"This project showcased Laureate's scientific expertise in developing suitable processes for clinical production of challenging proteins," noted Michiel E. Ultee, Ph.D., Laureate's Chief Scientific Officer. "We have successfully produced many fusion proteins, IgM antibodies, and other complex recombinant proteins for our clients to evaluate in the clinic."

Professor John H. Griffin, Ph.D., of The Scripps Research Institute and UCSD, and discoverer of 3K3A-APC, added, "During the development of the process for manufacturing 3K3A-APC, the Laureate process development team was invaluable in solving serious unforeseen impediments to the ultimate successful production of our product. It was a pleasure and a privilege to work hand-in-hand with this group of dedicated scientists."

About Laureate Biopharmaceutical Services, Inc. 
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit www.LBioS.com.

About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.

About ZZ Biotech, LLC
ZZ Biotech is headquartered in Houston, TX with a mission to develop innovative biological treatments for the aging and damaged brain, including those affected by stroke and other neurodegenerative disorders. ZZ Biotech is developing a genetically engineered variant of recombinant human wild-type activated Protein C (APC), named 3K3A-APC, that has reduced anticoagulant activity, but preserved cell-protective and anti-inflammatory activities compared to APC. ZZ Biotech is studying the safety and pharmacokinetics of 3K3A-APC in healthy human volunteers in an ongoing Phase 1 clinical study. For more information, please visit www.zzbiotech.com.

For more information, contact: Michiel E. Ultee, Ph.D., Chief Scientific Officer, Laureate Biopharma, at (609) 919-3390 or info@LBioS.com, or visit www.LBioS.com


'/>"/>
SOURCE Laureate Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimos Noninvasive Pleth Variability Index as Accurate as Invasive Stroke Volume Variation for Fluid Responsiveness Assessment in Cardiac Surgery
2. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
3. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
4. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
5. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
6. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
7. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
8. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
9. Lifeline Biotechnologies First Warning Systems
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
(Date:4/28/2016)... 2016 Treato , the ... announced today that it has been named a Cool ... in Life Sciences, 2016, Stephen Davies , ... focuses on life-science- oriented analytics, algorithms and smart machine ... doctors, confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 03, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 at the Wynn & ... conference for the specialty pharmacy industry, with thousands of pharmacy providers, pharma/biotech manufacturers, ...
(Date:5/3/2016)... ... 2016 , ... Diagnotes, a leader in digital healthcare communications, ... system in South Carolina, to provide its secure mobile communication platform. , “Healthcare ... drives workflow efficiencies and improves provider and patient satisfaction,” said Dr. Todd Rowland, ...
(Date:5/3/2016)... Atlanta, GA (PRWEB) , ... May 03, 2016 , ... Nationally recognized personal injury law ... Mother’s Day weekend by giving free roses to anyone who wants one for their Mother ... that we recognize the important valuable contributions of Mothers.” Monge goes on to say, ...
(Date:5/3/2016)... ... , ... Ogawa World USA introduced the first of its kind Ogawa ... Application. The Smart 3D combines the best in technological advancement, design, and massage capability ... specialized massage program, each user has a tailored experience unparalleled by any other massage ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the ... Information and Communication Technology (ICT) companies in the annual Branham300 listing. For 23 ... in Canada, as ranked by revenue. , “We are honored to be ...
Breaking Medicine News(10 mins):